ZyVersa Therapeutics, Inc.
ZVSA
$0.7151
$0.00711.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -23.28% | -17.73% | -47.96% | -34.57% | -56.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.56% | -21.81% | -46.52% | -38.45% | -65.75% |
| Operating Income | 27.56% | 21.81% | 46.52% | 38.45% | 65.75% |
| Income Before Tax | 89.78% | 17.28% | 96.81% | 38.43% | -156.98% |
| Income Tax Expenses | 99.50% | -- | 100.12% | -- | 20.00% |
| Earnings from Continuing Operations | 89.34% | 17.27% | 96.48% | 20.24% | -185.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.34% | 17.27% | 96.48% | 20.24% | -185.18% |
| EBIT | 27.56% | 21.81% | 46.52% | 38.45% | 65.75% |
| EBITDA | 27.46% | 21.80% | 46.55% | 38.47% | 65.78% |
| EPS Basic | 98.85% | 91.95% | 99.80% | 96.66% | -106,582.16% |
| Normalized Basic EPS | 91.35% | 91.86% | 96.73% | 97.42% | -13,864.86% |
| EPS Diluted | 98.85% | 91.95% | 99.80% | 96.66% | -106,582.16% |
| Normalized Diluted EPS | 91.35% | 91.86% | 96.73% | 97.42% | -13,864.86% |
| Average Basic Shares Outstanding | 826.62% | 915.83% | 1,537.06% | 2,289.27% | -99.77% |
| Average Diluted Shares Outstanding | 826.62% | 915.83% | 1,537.06% | 2,289.27% | -99.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |